Knowledge graph · Trial
Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy
COMPLETED
- Identifier
- CI-TRIAL-00045251
- Entity page
- /trial/NCT02699424 ↗
- Edges
- 1
- Neighbours
- 1 cancers
- Drawn
- 1 of 1 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy condition of …CONDITION_OFderived1 of 1 | ||||||||
| ← condition of | Malignant Prostate Neoplasm registry condition “Relapsed Prostate Cancer” mapped CURATED_BROADER | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
An edge is a relationship stated by a source (CIViC evidence item, ChEMBL indication or mechanism, openFDA approval) and kept with its native evidence level, direction and cancer context — CancerIndex never infers, merges or re-scales it. Rows marked are counts and measurements read from registries (ClinicalTrials.gov conditions and interventions, GDC/cBioPortal cohort frequencies ≥ 5 % with ≥ 20 cases affected, regulatory approval records): they say how often two entities co-occur in a registry, not that a source asserted a biological or clinical link. Trials are rolled up over the cancer and its descendants; approvals list authority, jurisdiction and date as published.